Are you interested in exploring ongoing clinical trials for at the University of Alabama at Birmingham?


Top 10 Hospitals and Doctors for Ovarian Cancer

ovarian cancer, best doctors, best hospitals

Ovarian cancer is the cancerous growth in the cells of ovary. This cancer is salient in a way that it often remains elusive until it has spread within the pelvis and abdomen. Ovarian cancer is often referred to as the "cancer that whispers" because its symptoms are vague and inconclusive, and a diagnosis is very seldom made until the cancer has reached advanced stage. Ovarian cancer is diagnosed in an estimated 20000 women in the U.S. each year and the 5-year relative survival rate is 92% if the treatment is started before the cancer has spread outside the ovary (stages IA and IB). To add to the woes, only 15% of all ovarian cancers are found at this early stage. Although it is a highly fatal disease, there is considerable variation in survival, and about one-third of patients survive at least 10 years. The first step in treatment of cancer is selection of doctor and hospital. We, at XpertDox, assayed billions of medically relevant and valid data points to give you the best, data-leveraged and scientific suggestion of the most suitable doctors and hospitals for ovarian cancer.


THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER: The Blanton-Davis Ovarian Cancer Research Program at MD Anderson is a multi-modal integration of education, research, patient care, prevention initiatives and therapeutic strategies focused on ovarian cancer. The program infuses innovative research into the causes, prevention, diagnostics and therapeutics of ovarian cancer. The program’s goals are to develop novel and targeted therapies for ovarian cancers, generating a new, granular understanding of the causes of ovarian cancer and devising new methods for diagnosing ovarian cancer. The Ovarian Cancer Research Lab, part of MD Anderson's Department of Experimental Therapeutics, focuses on the biology, identification, prevention and treatment of ovarian cancers.

MEMORIAL SLOAN-KETTERING CANCER CENTER: Memorial Sloan Kettering is internationally recognized as a leader in pioneering precise and cutting-edge ways to treat ovarian cancer, resulting in excellent outcomes. Memorial Sloan Kettering' specialists have stellar experience and vast depth and breadth of knowledge and are among the best in the world. The center has abundant experience providing comprehensive screening, inclusive counseling, and integrated treatment for ovarian cancer. Huge efforts are put to keep the focus on the advancement of the ovarian cancer therapeutics field and the establishment of superlative standards for unmatched patient care. Quality of Care Initiative thrives to provide continuous quality improvement across the full spectrum of ovarian cancer care and includes establishment of evidence-based care and process standards and deep-rooted commitment to continuous performance improvement.

YALE-NEW HAVEN HOSPITAL: The Gynecologic Cancers Program at Smilow Cancer Hospital uses a multidisciplinary approach for ovarian cancer treatment. Supported by a team of medical oncologists, radiation oncologists, surgeons, oncology nurses and researchers, their cancer team is top-notch in terms of cancer detection, prevention, research, education, and treatment. In the continued quest against ovarian cancer, Yale Cancer Center (YCC) has ruled the roost with a long history of professional excellence. At Yale NewHaven Health, Smilow Cancer Hospital, there is inbound impetus of understanding the grass-root level mechanisms of cancer biology and in developing effective therapies for the treatment of ovarian cancer. Though sustained efforts blended with passion to eradicate cancer, there has been huge progress in the fields of advance cancer research, education, prevention, and patient care, as well as community outreach.

BRIGHAM AND WOMEN'S HOSPITAL: Brigham and Women's Hospital is one of the world's most noteworthy cancer research and treatment institutions. Because of this, the Gynecologic Oncology Program at Brigham and Women's Hospital offers considerable upper-edge in ovarian cancer treatment which rests on fundamental cancer biology and is based as per the protocols of latest ovarian cancer research. Brigham and Women's Hospital is a world leader in minimally invasive surgical approaches to ovarian and other gynecologic cancers. The title of being a major research institution keeps it in an advantageous position where the patients may have the opportunity to participate in focused clinical trials where the most advanced forms of ovarian cancer treatment are being assessed and developed. At any given time, clinical trials are in progress to develop new cancer-fighting therapies, to learn about the genes and DNA that cause cancer, and to discover innovative ways of preventing development of cancer. Their researchers are exploring the cancer therapeutics from every possible perspective, and also evaluating new alternatives to treat ovarian cancer such as biologic and targeted therapies.

MAYO CLINIC HOSPITAL ROCHESTER: Holding the reputation of one of the most notable Gynecology hospital in the nation, Mayo Clinic Hospital Rochester is spearheading the progress in the domain of ovarian cancer. Lined by exceptionally qualified and experienced medical staff and governed by cancer-centric research visionaries, Mayo Clinic Hospital Rochester has state-of-the-art facilities to tackle ovarian cancer with latest and leading-edge treatment. On top of this, the center offers advanced diagnostic facilities, clinical trial participation, research-fueled therapies and unparalleled compassion.

MASSACHUSETTS GENERAL HOSPITAL: The Center for Gynecologic Oncology provides compassionate and consummate care for patients with ovarian cancer. The doctors and other medical staff stand committed to provide every patient world-class cancer care with unsurpassed clinical outcomes based on the most advanced measures for preserving sexual, reproductive and hormone function. In addition to traditional approaches, Center for Gynecologic Oncology offers many innovative approaches to the diagnosis and treatment of ovarian cancer, such as access to bleeding-edge medical therapies, latest surgical innovations with special emphasis on minimally invasive procedures and promotion of integrative therapies. Gynecologic cancer pathologists at Massachusetts Gneral Hospital are internationally recognized and regularly participate in tumor board meetings, sharing information about each patient’s cancer with the entire therapeutics team to help guide care planning. The radiation teams are specialized and offer a full spectrum of computer-controlled internal and external radiation treatments for ovarian cancer.

SWEDISH MEDICAL CENTER: At the Swedish Cancer Institute, women with ovarian cancer receive outstanding care through a nationally recognized gynecological cancer program. This includes the matchless expertise of a renowned team of physicians and other medical specialists. All ovarian-cancer patients are provided a multidisciplinary and unequaled approach to care that encompasses finest imaging techniques, the choicest and latest in treatment options and a thoroughgoing selection of high-quality support services. Swedish is also one of the founders of the Marsha Rivkin Center for Ovarian Cancer Research, which is absolutely dedicated to perfecting research, polishing patient-centric care, saving lives and reducing suffering through superlative treatment plans, early detection and prevention of ovarian cancer.

CEDARS-SINAI MEDICAL CENTER: The ovarian cancer expert team at Cedars Sinai is made of up of top-tier cancer doctors, surgeons, pathologists, radiologists, researchers, nurses and support staff. Using innovative technology, this team provides the patients with the best treatment outcomes using latest research tools. The Gilda Radner Hereditary Cancer Program, a dedicated and outstanding program of Cedars-Sinai Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, consists of several peerless research studies for women at highest risk for ovarian cancers. The Gilda Radner Hereditary Cancer Program has contributed invaluable data (biomarker data, genetic predisposition and factors related to familial risk) for the understanding of ovarian cancer in high-risk women. The doctors, researchers and scientists are committed to advances in ovarian cancer detection, prevention and treatment modalities. Women's healthcare is a top priority at Cedars-Sinai and ovarian cancer patients get comprehensive, consummate and compassionate care in the form of second to none diagnostics and avant-garde therapeutics.

DUKE UNIVERSITY HOSPITAL: Duke’s holds the reputation of a clinical juggernaut in treating ovarian cancers. Its nationally ranked ovarian cancer experts detect and treat cancer by drawing upon latest research findings and using cutting-edge, latest medical tools, and their ongoing ovarian cancer specific clinical trials ensure the most reasonable and effective treatment plan for the particular stage and type of every ovarian cancer patient. As a National Cancer Institute-designated Comprehensive Cancer Center, Duke's a formidable force in the realms of ovarian cancer care and their ovarian cancer team is recognized for deep-probing novel therapies through ongoing clinical trials. Duke University Hospital is an integral part of the National Comprehensive Cancer Network (NCCN), an alliance of the nation’s pioneering and commanding cancer centers dedicated to all-encompassing care for the ovarian cancer patients. They have dedicated gynecologic oncologists, genetic counselors, immunotherapists and cancer radiologists and their comprehensive cancer support services range from helping patients keep the side effects of treatment at the minimum to coping with the emotional and psychological effects of diagnosis and treatment.

JOHNS HOPKINS HOSPITAL: The nationally recognized cancer experts at John Hopkins provide profound commitment to partnering with patients who have ovarian cancer to provide the best care possible. Their intense drive to learn everything in the realms of latest cancer care, unwavering dedication to improving the management and outcome of ovarian cancer and continual quest to make significant inroads in the fight against ovarian cancer provides hope for the future. Over the past few decades, the gynecologic oncologists and cancer pathologists have gained an unprecedented reputation for diagnosing rare and intricate ovarian cancers. They have successfully developed a global consultation service in which patients from all corners of the world approach them for second opinions and ovarian cancer consultations. On the research front, their pathology scientists and clinicians lead pioneering clinical trials that pave new roads of delivering chemotherapy and designing new approaches of cancer care. At Johns Hopkins, the latest treatments in ovarian cancer is not just offered, it is developed also for the world to follow.  From basic science discoveries uncovering complex genetic mechanisms underlying the development of ovarian cancer to spearheading clinical research, the experts at John Hopkins apply unprecedented knowledge and expertise in treating the patients of ovarian cancer by combining clinical and research expertise into matchless care.


Andrew Berchuck, MD: Dr. Andrew Berchuck is Director of the Duke Division of Gynecologic Oncology and also holds the James M. Ingram Distinguished Professorship. He is a leading force in gynecologic oncology with active and expert involvement in the surgical and chemotherapy management of women with ovarian cancers. Having published over 300 peer-reviewed papers in the areas of ovarian cancer, endometrial cancer and lower genital tract cancers, Dr. Berchuck developed a research program that focuses heavily on the molecular-genetic alterations involved in malignant transformation of the ovarian epithelium.

William A Cliby, MD: Dr. William A Cliby is Consultant, Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, Mayo Clinic, Rochester, Minnesota. He has consistently focused on quality of care and development of novel methods in management of ovarian cancer with a specific interest in surgical management. Through ground-breaking clinical and research work, he has observed a strong link between radical surgical excision and improved patient survival and works relentlessly to increase rates of surgical resection nationally.

Thomas J Rutherford, MD: Dr. Thomas J Rutherford serves as the Director, College of Medicine Obstetrics & Gynecology and Professor & Division Director, College of Medicine Obstetrics & Gynecology at University of South Florida. He is nationally recognized gynecologic oncologist, an expert in ovarian cancer treatment and research. Dr. Rutherford came to USF from Western Connecticut Health Network (WCHN), where he expanded cancer services and helped create a new model of cancer care delivery that built upon the strengths of existing programs to enhance accessible, high-quality and integrated cancer care.

Anil K Sood, MD: Dr. Anil K. Sood is a physician-scientist at MD Anderson Center, The University of Texas. With a deep-rooted interest in refining the understanding of the mechanisms underlying ovarian cancer, Dr. Sood has constantly been the guiding force for development of novel methods to understand, detect and treat ovarian cancer. He is hugely involved in cancer research which is focused on developing new biologically targeted therapies, and probing the role of non-coding RNAs as biomarkers and for myriad therapeutic applications.

Shasikant B Lele, MD: Dr. Shasikant B Lele is the Clinical Chief of Gynecologic Oncology and holds the Clinical Chair, Division of Surgical Subspecialties at Roswell Park Comprehensive Cancer Center. A recognized national leader in the realms of ovarian cancer treatment, Dr. Lele serves as the Clinical Professor of Gynecology & Obstetrics, Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo.

Robert E Bristow, MD: Dr. Robert E. Bristow pioneering sophisticated techniques for the management of gynecologic cancers. He’s recognized internationally as a leading expert in ovarian oncology. Also, he has authored and published several books and medical research papers on ovarian cancer. Recently, he was appointed to the UC Irvine School of Medicine’s Philip J. DiSaia Chair in Gynecologic Oncology, becoming the first holder of the chair named for the university’s highly esteemed former chief of the Division of Gynecologic Oncology.

Dan A Silasi, MD: Dr. Dan-Arin Silasi is Associate Professor of Obstetrics, Gynecology, and Reproductive Sciences at The Yale School of Medicine. He specializes in cytoreductive surgery for patients with advanced ovarian cancer, minimally invasive procedures (advanced laparoscopy and robotics) for patients with ovarian malignancies or complex benign gynecologic conditions, robotic fertility sparing surgery for patients with ovarian cancer. He provides the novel and cutting-edge chemotherapeutic management for patients with ovarian malignancies.

John O Schorge, MD: Dr. John O Schorge is a Gynecologic Oncologist at Tufts Medical Center. He has exceptional expertise in screening, diagnosis and treatment of ovarian cancers. He received his medical degree from Vanderbilt University School of Medicine and has been in practice for more than 20 years. He is the leading-edge provider of chemotherapeutic management for patients with ovarian malignancies.

David M Gershenson, MD: Dr. Gershenson is Professor and J. Taylor Wharton, M.D., Distinguished Chair in Gynecologic Oncology, Department of Gynecologic Oncology and Reproductive Medicine at the University of Texas MD Anderson Cancer Center. Since 2006, he has served as a Director of the American Board of Obstetrics and Gynecology and also holds the position of Editor Emeritus of the journal Gynecologic Oncology.

Bradley J Monk, MD: Dr. Bradley J Monk is a Director and Professor of the Division of Gynecologic Oncology at Creighton University School of Medicine, St. Joseph’s Hospital and Medical Center in Phoenix, Arizona. He has stellar clinical experience in prevention, diagnostics and treatment of ovarian cancer and other gynecologic malignancies. Having peerless collection of published research papers and articles in the realms of ovarian and other gynaecologic malignancies, Dr. Monk continuously imbibes latest treatment tools in his practice